CoChat

Rationale and Design of the SERVE-HF Study: Treatment of Sleep-Disordered Breathing with Predominant Central Sleep Apnoea with Adaptive Servo-Ventilation in Patients with Chronic Heart Failure

Open access
Cowie, Martin R., Woehrle, Holger, Wegscheider, Karl, Angermann, Christiane, d’Ortho, Marie-Pia, Erdmann, Erland, Levy, Patrick, Simonds, Anita, Somers, Virend K., Zannad, Faiez, Teschler, Helmut · 2013 · European Journal of Heart Failure
Cited by 123

The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.

Abstract

Aims: Central sleep apnoea/Cheyne–Stokes respiration (CSA/CSR) is a risk factor for increased mortality and morbidity in heart failure (HF). Adaptive servo-ventilation (ASV) is a non-invasive ventilation modality for the treatment of CSA/CSR in patients with HF. Methods: SERVE-HF is a multinational, multicentre, randomized, parallel trial designed to assess the effects of addition of ASV (PaceWave™, AutoSet CS™; ResMed) to optimal medical management compared with medical management alone (control group) in patients with symptomatic chronic HF, LVEF ≤45%, and predominant CSA. The trial is based on an event-driven group sequential design, and the final analysis will be performed when 651 events have been observed or the study is terminated at one of the two interim analyses. The aim is to randomize ∼1200 patients to be followed for a minimum of 2 years. Patients are to stay in the trial up to study termination. The first patient was randomized in February 2008 and the study is expected to end mid 2015. The primary combined endpoint is the time to first event of all-cause death, unplanned hospitalization (or unplanned prolongation of a planned hospitalization) for worsening (chronic) HF, cardiac transplantation, resuscitation of sudden cardiac arrest, or appropriate life-saving shock for ventricular fibrillation or fast ventricular tachycardia in implantable cardioverter defibrillator patients. Perspectives: The SERVE-HF study is a randomized study that will provide important data on the effect of treatment with ASV on morbidity and mortality, as well as the cost-effectiveness of this therapy, in patients with chronic HF and predominantly CSA/CSR. Trial registration: ISRCTN19572887

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/eurjhf/hft051

Cites

15 of 15 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 15 references

Cited by

See all 123

Metadata

Authors
Cowie, M. R., Woehrle, H., Wegscheider, K., Angermann, C., d’Ortho, M.-P., Erdmann, E., Levy, P., Simonds, A., Somers, V. K., Zannad, F., & Teschler, H.
Venue
European Journal of Heart Failure
Published
2013-08-01
Volume
15
Issue
8
Pages
937-943
ISSN
  • 1388-9842 (ISSN-L)
  • 1879-0844
OpenAlex
W2025154415
Cited by
123
References
15
FWCI
17.14
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Rationale and Design of the SERVE-HF Study: Treatment of Sleep-Disordered Breathing with Predominant Central Sleep Apnoea with Adaptive Servo-Ventilation in Patients with Chronic Heart Failure. https://app.cochat.ai/papers/10.1093/eurjhf/hft051
The paper
Cowie, M. R., Woehrle, H., Wegscheider, K., Angermann, C., d’Ortho, M.-P., Erdmann, E., Levy, P., Simonds, A., Somers, V. K., Zannad, F., & Teschler, H. (2013). Rationale and Design of the SERVE-HF Study: Treatment of Sleep-Disordered Breathing with Predominant Central Sleep Apnoea with Adaptive Servo-Ventilation in Patients with Chronic Heart Failure. European Journal of Heart Failure. https://doi.org/10.1093/eurjhf/hft051

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.